UCB doubles down on TCEs with $2.2bn Candid buyout
UCB has agreed to acquire Candid Therapeutics and its range of autoimmune and inflammatory disease-focused novel T-cell engager (TCE) candidates,…
05 May 2026
Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara
Sunshine Lake Pharma, Lannett and its wholly owned subsidiary Lanexa Biologics have received approval from the US Food and Drug Administration (FDA) for Langlara (insulin glargine-aldy), an interchangeable biosimilar of…
05 May 2026
Latus Bio secures $97m in funding to boost gene therapy access
Latus Bio has closed a $97m Series A financing round to expand the reach of its gene therapies to wider patient groups. The financing includes a $43m extension led by…
04 May 2026
Arrowhead’s Redemplo secures Australian TGA approval for FCS therapy
Arrowhead Pharmaceuticals has received approval from the Australian Therapeutic Goods Administration (TGA) for Redemplo (plozasiran) to treat familial chylomicronemia syndrome (FCS). The therapy is approved as an add-on to diet,…
04 May 2026
Novo Nordisk to launch Ozempic for type 2 diabetes in US
Novo Nordisk is set to launch Ozempic, its oral glucagon-like peptide-1 (GLP-1) receptor agonist pill for adults with type 2 diabetes, in the US. The Ozempic oral pill, approved by…
01 May 2026
Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation
Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and bupropion HCl) to treat agitation associated with dementia due to Alzheimer’s. Auvelity is…
01 May 2026
Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening
Buoyed by yet another strong quarter fuelled by obesity drug demand, Eli Lilly has raised its sales expectations for the year ahead. Revenue for Lilly in Q1 2026 reached $19.8bn,…